Prostate cancer screening company Prostate Conditions Education Council (PCEC) said on Monday that it is providing free prostate cancer testing to men across the country following the recent fall in delayed diagnosis due to fewer doctor visits and reduced testing in the face of ongoing COVID-19 pandemic.
Prostate cancer is the second leading cause of cancer death in men, but easily treated when caught early, but too often it is not diagnosed early. The Council's new programme allows for men to gain access to a prostate specific antigen (PSA) blood test by visiting a national network for laboratories for the simple blood test and those who are unable to visit a laboratory. The free testing programme will take place during September and will continue throughout the fall season until the resources for the programme are depleted.
Additionally, the Council has aligned with at-home digital screening provider imaware to promote testing so that men can take assess their prostate cancer risk. The families can sign up for the free prostate cancer screening by visiting www.prostateevents.org.
Based in Houston, Texas, imaware has provided an essential healthcare service to thousands of Americans for COVID-19, cardiovascular disease, prostate cancer and autoimmune disorders.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca